NCT02075593 - ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 17, 2014

Primary Completion Date

October 22, 2018

Study Completion Date

September 15, 2021

Conditions

Infection, Human Immunodeficiency VirusHIV InfectionsArthralgia

Interventions

DRUG

DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets

The DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablet is a purple, oval, biconvex tablets. The tablet contains 52.6 mg DTG sodium which is equivalent to 50 mg DTG free acid, 702 mg ABC sulphate which is equivalent to 600 mg ABC and 300 mg 3TC.

Trial Locations (3)

28046

GSK Investigational Site, Madrid

196645

GSK Investigational Site, Saint Petersburg

302040

GSK Investigational Site, Oryol